Results 141 to 150 of about 76,806 (261)

Elevated lymphoma risk in patients with chronic pruritus and chronic prurigo

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Chronic pruritus (CP) and chronic prurigo (CPG, including prurigo nodularis) are prevalent, debilitating diseases with diverse comorbidities, including malignancies. This retrospective cohort study evaluated the prevalence and risk of lymphoma in CP and CPG patients, including key risk factors, and sex‐ and ancestry ...
Svenja Royeck, Henning Olbrich, Steffen Koschmieder, Claudia Zeidler, Felix Witte, Konstantin Agelopoulos, Henning Wiegmann, Michael Storck, Johannes Benedict Oehm, Ralf J. Ludwig, Sonja Ständer   +10 more
wiley   +1 more source

Quantitative longitudinal photoacoustic imaging of vascular oxygenation for therapy response monitoring in Non-Hodgkin lymphoma. [PDF]

Photoacoustics
Shi J, Fan Y, Mi J, Mao Q, Huang Y, Ta D, Feng T, Chen L.   +7 more
europepmc   +1 more source

Current state of medical care for patients with mycosis fungoides and Sézary syndrome at a German university hospital – a cross‐sectional study

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background Studies on the state of medical care for patients with cutaneous T‐cell lymphoma (CTCL) are limited. To date, only secondary data analyses are available for Germany. Patients and Methods Cross‐sectional study conducted over a one‐year recruitment period (01 March 2024 to 28 February 2025) in the dermatological department of a German ...
Inga Hansen‐Abeck, Larissa Kölln, Finn Abeck, Glenn Geidel, Stefan W. Schneider, Nina Booken   +5 more
wiley   +1 more source

Breast Mass as an Atypical Presentation of Non-Hodgkin Lymphoma. [PDF]

Cureus
Figueiredo F, Valido T, Chumbo C, Gomes G, Rocha M.   +4 more
europepmc   +1 more source

The different face of skin‐rash induced by brentuximab vedotin

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background: Brentuximab vedotin (BV) is a targeted therapy for CD30‐expressing lymphomas, including Hodgkin lymphoma (HL) and cutaneous T‐cell lymphoma (CTCL). While peripheral neuropathy is the most common adverse event, BV‐induced skin rashes are less frequent and not well characterized.
Alessandro Pileri, Tullio Brunetti, Serena Rupoli, Gianluca Cafasso, Corrado Zengarini, Staphano Cedirian, Federico Bardazzi, Cosimo Misciali, Michela Starace, Claudio Agostinelli, Gaia Goteri, Erika Morsia   +11 more
wiley   +1 more source

Correction to "Transformation of Classical Hodgkin Lymphoma Into Non-Hodgkin Lymphoma: Three Case Reports From the West Bank". [PDF]

Case Rep Oncol Med
europepmc   +1 more source

Secondary primary malignancies in indolent non-Hodgkin lymphoma patients receiving frontline bendamustine-rituximab. [PDF]

Cancer
Davies GA, Prica A, Ante Z, Liu N, Pond GR, Balitsky AK, Suleman A, Mozessohn L.   +7 more
europepmc   +1 more source

Emerging Techniques in Minimally Invasive Surgery in Hematologic Malignancies

European Journal of Haematology, EarlyView.
ABSTRACT Hematologic malignancies represent the most common cancers in children. While the mainstays of treatment are chemotherapy and potentially hematopoietic stem cell transplant, minimally invasive surgery (MIS) has a role in the diagnosis and management of complications related both to disease and therapy as well as common pediatric surgical ...
Alejandro Chara, Katlyn G. McKay, Harold N. Lovvorn III, Joseph C. Fusco   +3 more
wiley   +1 more source

NEK2 drives pathogenesis, drug resistance, and LMP1 expression in EBV-positive non-Hodgkin lymphoma. [PDF]

Proc Natl Acad Sci U S A
White MC, Lange PT, Stewart J, Damania B.   +3 more
europepmc   +1 more source

Post‐Transplant Bendamustine as a Platform for Immune Modulation After Allogeneic Hematopoietic Cell Transplantation

European Journal of Haematology, EarlyView.
ABSTRACT Post‐transplant cyclophosphamide (PT‐CY) remains the standard of care for graft‐versus‐host disease (GvHD) prophylaxis in haploidentical hematopoietic cell transplantation (HCT), yet relapse, delayed immune reconstitution, infections, and organ toxicity represent persistent and clinically meaningful limitations.
Megan J. Cracchiolo, Richard J. Simpson, Emmanuel Katsanis   +2 more
wiley   +1 more source